Valuation: Botanix Pharmaceuticals Limited

Market Cap 35.58M 24.97M 22.33M 20.66M 18.7M 35M 2.38B 249M 98.32M 1.24B 93.71M 91.71M 3.93B P/E 2027 *
-1.3x
P/E 2028 * -
Enterprise Value 40.58M 28.48M 25.46M 23.56M 21.33M 39.92M 2.71B 283M 112M 1.42B 107M 105M 4.49B EV / Sales 2027 *
0.67x
EV / Sales 2028 * 0.23x
Free-Float
89.38%
Yield 2027 *
-
Yield 2028 * -
1 day-11.54%
1 week-4.17%
Current month-36.11%
1 month-36.11%
3 months-45.24%
6 months-64.06%
Current year-91.48%
1 week 0.01
Extreme 0.011
0.01
1 month 0.01
Extreme 0.011
0.02
Current year 0.01
Extreme 0.011
0.15
1 year 0.01
Extreme 0.011
0.15
3 years 0.01
Extreme 0.011
0.54
5 years 0.01
Extreme 0.011
0.54
10 years 0.01
Extreme 0.011
0.54
Manager TitleAgeSince
Chief Executive Officer - 2023-08-23
Director of Finance/CFO - 2024-03-25
President 67 2019-05-19
Director TitleAgeSince
Director/Board Member - 2016-06-30
Chairman 67 2019-07-17
Director/Board Member - 2026-10-17
Date Insider Type Main position Quantity % Market Cap. Importance
4/24/26 Free

Director

1,666,667 0.0751%
4/24/26 Free

Chairman

1,666,667 0.0751%
4/24/26 Free

Director

1,666,667 0.0751%
Change 5-day change 1-year change 3-year change Capi.($)
-11.54%-4.17%-91.79%-91.79% 23.1M
+0.45%+3.13%+54.96%+125.16% 1,135B
+0.94%+4.93%+39.86%+78.72% 635B
+0.39%+1.44%+25.77%+97.48% 505B
+1.43%+4.31%+46.20%+67.12% 378B
-3.21%-2.10%+60.72%+33.22% 358B
-0.41%+2.64%+22.48%+49.82% 295B
+0.23%+3.66%+2.57%+23.69% 266B
+1.22%+4.63%+52.40%+64.85% 237B
+1.70%+3.67%+31.21%+102.15% 193B
Average -0.91%+1.74%+24.44%+55.04% 400.37B
Weighted average by Cap. +0.42%+2.85%+41.40%+83.61%

Financials

2027 *2028 *
Net sales 60.8M 42.67M 38.16M 35.3M 31.96M 59.82M 4.06B 425M 168M 2.12B 160M 157M 6.72B 119M 83.33M 74.51M 68.94M 62.42M 117M 7.93B 830M 328M 4.15B 313M 306M 13.13B
Net income -43.47M -30.51M -27.28M -25.24M -22.85M -42.77M -2.9B -304M -120M -1.52B -114M -112M -4.81B -1.93M -1.36M -1.21M -1.12M -1.02M -1.9M -129M -13.51M -5.34M -67.52M -5.09M -4.98M -214M
Net Debt 5M 3.51M 3.14M 2.9M 2.63M 4.92M 334M 34.93M 13.82M 175M 13.17M 12.89M 553M -7.9M -5.54M -4.96M -4.59M -4.15M -7.77M -527M -55.19M -21.83M -276M -20.81M -20.36M -874M
Projected Income Statement - Annual - Botanix Pharmaceuticals Limited
Logo Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).
Employees
11
Date Price Change Volume
26-10-26 A$0.0115 -11.54% 19,355,860
26-10-26 A$0.0130 +8.33% 7,598,231
26-10-23 A$0.0120 -7.69% 607,115
26-10-22 A$0.0130 0.00% 3,056,593
26-10-21 A$0.0130 +8.33% 7,291,581
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Botanix Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0130AUD
Average target price
0.4833AUD
Spread / Average Target
+3,617.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Botanix Pharmaceuticals Limited